Catalogo dei prodotti della ricerca

GIUSTI, RAFFAELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 979
EU - Europa 559
AS - Asia 299
AF - Africa 24
SA - Sud America 9
OC - Oceania 1
Totale 1.871
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 962
IT - Italia 231
SE - Svezia 160
SG - Singapore 147
IN - India 61
CN - Cina 43
FI - Finlandia 38
DE - Germania 31
BG - Bulgaria 26
TG - Togo 22
ID - Indonesia 15
CA - Canada 13
HK - Hong Kong 11
IE - Irlanda 11
NL - Olanda 10
GB - Regno Unito 9
RO - Romania 8
ES - Italia 7
FR - Francia 7
AR - Argentina 6
JP - Giappone 5
TR - Turchia 5
BE - Belgio 4
PT - Portogallo 4
CZ - Repubblica Ceca 3
IR - Iran 3
MX - Messico 3
RU - Federazione Russa 3
UA - Ucraina 3
IL - Israele 2
KR - Corea 2
VN - Vietnam 2
AU - Australia 1
CH - Svizzera 1
CL - Cile 1
CR - Costa Rica 1
EC - Ecuador 1
KG - Kirghizistan 1
KZ - Kazakistan 1
MK - Macedonia 1
NG - Nigeria 1
NO - Norvegia 1
PE - Perù 1
PL - Polonia 1
TW - Taiwan 1
ZA - Sudafrica 1
Totale 1.871
Salva come PNG Salva come JPEG
Città #
Fairfield 132
Singapore 108
Ashburn 84
Rome 71
Chandler 60
Cambridge 56
Houston 52
Santa Clara 49
Woodbridge 49
Wilmington 48
Seattle 41
Stockholm 40
Princeton 33
San Paolo di Civitate 31
Helsinki 30
Ann Arbor 28
Sofia 26
Lomé 22
Lawrence 21
New York 20
Milan 18
Millbury 17
San Diego 17
Boston 16
Beijing 15
Jakarta 15
Andover 12
Dearborn 10
Bremen 9
Dublin 9
Boardman 8
Norwalk 8
Padova 8
Toronto 7
Federal 6
Fremont 6
Hong Kong 6
Plano 6
Washington 6
Istanbul 5
Shanghai 5
Bloomfield Hills 4
Brussels 4
Madrid 4
Mannheim 4
Ottawa 4
Sacramento 4
Barcelona 3
Catania 3
Changsha 3
Falkenstein 3
Groningen 3
Lappeenranta 3
Latina 3
Leawood 3
Breda 2
Bühl 2
Central 2
Chicago 2
Durham 2
Ercolano 2
Fuzhou 2
Imola 2
Kalāheo 2
Lisbon 2
Livorno 2
London 2
Marsicovetere 2
Mexico City 2
Morlupo 2
Naples 2
Pomezia 2
Pune 2
Raleigh 2
Reggio Emilia 2
Rizziconi 2
Takamatsu 2
Thiene 2
Tokyo 2
Wuhan 2
Abuja 1
Almaty 1
Arnsberg 1
Avellino 1
Balasore 1
Bari 1
Beauharnois 1
Bishkek 1
Brindisi 1
Buffalo 1
Cagliari 1
Chengdu 1
Chennai 1
Drancy 1
Faenza 1
Gavirate 1
Guangzhou 1
Guayaquil 1
Guidonia 1
Hanoi 1
Totale 1.328
Salva come PNG Salva come JPEG
Nome #
A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab 107
Pharmacogenetic Approach to Toxicity in Breast Cancer Patients Treated with Taxanes 101
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 100
New driver alterations in non-small cell lung cancer. A narrative review 80
Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment 80
Pharmacogenetic assessment of toxicity in patients treated with taxane-based chemotherapy for solid tumors 76
Genetic polymorphism can help physician choosing the best lung cancer chemotherapy 74
Unexpected serious aplastic anemia from PD-1 inhibitors. beyond what we know 73
Ceritinib compassionate use for patients with crizotinib-refractory, anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer 72
Is there a place for crizotinib in c-MET alterations? A case of efficacy in ALK positive NSCLC patient with secondary c-MET amplification 66
Tryptophan Catabolism as Immune Mechanism of Primary Resistance to Anti-PD-1 63
KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden 62
KEAP1 and TP53 frame genomic, evolutionary and immunological subtypes of lung adenocarcinoma with different sensitivity to immunotherapy 62
Multidisciplinary approach to fetal adenocarcinoma of the lung: A case report 60
CDKN2A/B gene loss and MDM2 alteration as a potential molecular signature for hyperprogressive disease in advanced NSCLC: A next-generation-sequencing approach 56
Efficacy of immunotherapy in lung cancer with co-occurring mutations in NOTCH and homologous repair genes 55
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50% 52
null 50
Next-Generation Sequencing in Clinical Practice. Is It a Cost-Saving Alternative to a Single-Gene Testing Approach? 50
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%. A multicenter study with external validation 49
Knowledge and attitudes of Italian medical oncologists and palliative care physicians toward medical use of cannabis in cancer care. a national survey 49
Palliative- and non-palliative indications for glucocorticoids use in course of immune-checkpoint inhibition. Current evidence and future perspectives 48
Statins and immunotherapy. Togetherness makes strength The potential effect of statins on immunotherapy for NSCLC 44
PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort 41
Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer 40
Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors. Prospective analysis from a multicentre observational trial by FICOG 39
Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients. a multicenter study of clinicians’ attitudes 39
Surgical and survival outcomes with perioperative or neoadjuvant immune-checkpoint inhibitors combined with platinum-based chemotherapy in resectable NSCLC: A systematic review and meta-analysis of randomised clinical trials 29
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status 29
Health as a human right, the right to life and the freedom to choose 28
Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario 25
Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors among Patients Aged 80 Years or Older with Cancer: A Multicenter International Cohort Study 23
EP08.02-046 Activity of OsimeRTInib in NSCLC with Uncommon EGFR Mutations: Retrospective Observational Multicenter Study (ARTICUNO) 17
1576P Efficacy of antiemetic regimens for highly emetogenic chemotherapy-induced nausea and vomiting: A network meta-analysis 17
Efficacy and safety of Antiemetic Regimens for Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Network Meta-Analysis 17
Complete Tumor Response with Afatinib 20 mg Daily in EGFR-Mutated Non-small Cell Lung Cancer: A Case Report 17
null 17
null 17
10P Family history of cancer correlates with improved outcome from immunotherapy in NSCLC independent of somatic DNA damage response gene status 16
[Immunotherapy in non-small cell lung cancer patients: back to the future.] 15
Impact of influenza vaccination on survival of patients with advanced cancer receiving immune checkpoint inhibitors (INVIDIa-2. Final results of the multicentre, prospective, observational study 14
Management of overlapping immune-related myocarditis, myositis, and myasthenia in a young patient with advanced NSCLC: a case report 14
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy 14
ACCESS TO EARLY PHASE CLINICAL TRIALS AT THE TIME OF THE COVID-19 PANDEMIC: AN ITALIAN SURVEY 12
Exploring Genomic Biomarkers for Pembrolizumab Response: A Real-World Approach and Patient Similarity Network Analysis Reveal DNA Response and Repair Gene Mutations as a Signature 12
null 10
null 10
Safety of extended interval dosing immune checkpoint inhibitors. A multicenter cohort study 7
L’immunoterapia nel tumore del polmone non a piccole cellule: ritorno al futuro 6
Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study 6
Training and telemedicine: the key to the palliative medicine specialist shortage? 5
Improved Event-Free Survival After Complete or Major Pathologic Response in Patients With Resectable NSCLC Treated With Neoadjuvant Chemoimmunotherapy Regardless of Adjuvant Treatment: A Systematic Review and Individual Patient Data Meta-Analysis 5
Totale 2.070
Salva come PNG Salva come JPEG
Categoria #
all - tutte 8.454
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.454
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020158 0 0 0 0 0 26 27 19 29 29 16 12
2020/2021217 12 8 13 15 2 6 16 29 22 34 24 36
2021/2022380 8 6 13 13 56 16 23 24 40 31 100 50
2022/2023443 81 108 41 27 40 30 5 63 31 4 9 4
2023/2024325 17 36 14 25 41 68 6 42 1 25 20 30
2024/2025342 35 61 49 65 85 47 0 0 0 0 0 0
Totale 2.070